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ABSTRACT 
 
 
 
The WHO (World Health Organization) estimates that 80% of the world’s population 
use Complementary Medicines (CMs) as their primary source of healthcare. Similar 
figures have been reported in the South African population (Siegfried &Hughes, 
2012: 2). The high numbers of CMs users in South Africa (S.A) raises considerable 
questions about how best to safeguard patient and population health, and what 
responsibilities the government has towards regulation of medicines and 
practitioners. This, in turn raises the issues of how best to assess CMs – and thus 
whether clinical trials are an appropriate method of assessment. 
 
The considerable difference between the systems of CMs and Allopathic Medicines 
raises concerns when applying clinical trial practices to CMs assessment. Clinical 
trials, as the gold standard for assessing medical efficacy in Allopathic Medicine, 
reflect specific interpretations of medicine and health. It has been noted that the key 
practices in clinical trials for Allopathic Medicines such as randomisation, blinding 
and placebo can be very difficult to adhere to when investigating CMs. Thus, the use 
of clinical trials to assess CMs raises a range of different concerns, from the validity 
of the trials to the potential harm to trial participants. 
 
There is considerable interest in S.A to improve legislation governing the widespread 
use of CMs. Nonetheless, the development of legislative oversight requires further 
consideration. In this research report, I will be critically interrogating the current 
legislation in S.A from an ethical perspective to identify areas requiring further 
attention. These issues include threats to participant well-being, threats to the 
efficacy of the trials, and long-term threats caused by potentially incomplete trial data. 
My research considers ways in which these ethical considerations can be 
ameliorated by directed changes to the legislation.  This research report will conclude 
by offering a range of recommendations for improvement to the governance of CMs 
clinical trials in S.A. The recommendations are made to the relevant departments 
which are making decisions with regards to clinical trials in S.A. 
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CHAPTER 1-DIFFERING APPROACHES TO HEALTH AND WELL BEING: 
COMPLEMENTARY MEDICINES AND ALLOPATHIC MEDICINES 
 
 
This chapter outlines the differences between Complementary Medicines (CMs) 
and Allopathic Medicines using existing literature. In order to discuss legislation 
and oversight of CMs it is first important to understand the terminology, what are 
the problems and why do we need to discuss it. In this chapter, the definition of a 
Medicine according to the Medicines Act 101 of 1965 (1965:3) which means “any 
substance or mixture of substances used or purporting to be suitable for use or 
manufactured or sold for use in- (a) the diagnosis, treatment, mitigation, 
modification or prevention of disease, abnormal physical or mental state or the 
symptoms thereof in man; or (b) restoring, correcting or modifying any somatic or 
psychic or organic function in man, and includes any veterinary medicine” is used. 
 
The types of ethical issues that this research report was focusing on were threats 
to participant well-being, threats to the efficacy of the trials and long-term threats 
caused by potentially incomplete trial data. The research looked at issues of 
informed consent, autonomy, justice, beneficence and non-maleficence. These 
issues are from a policy and governance perspective and they do not necessarily 
delving in to patient-related issues or intellectual property/ownership issues. 
 
1.1 INTRODUCTION 
 
In this section, the definitions of Allopathic Medicines and CMs will be provided. 
The differences between the two systems of healthcare provision will also be 
examined. While the uses of Allopathic medicines are exponentially increasing, 
CMs1 remain widely used around the world as a primary means of health care 
(Boon et al., 2006:21). People use CMs due to a number of reasons such as their 
cultural use, historical use, availability and the fact that there are no options for 
them to effectively engage with allopathic treatments (Witkowksi, 2002:456). 
                                            
1 For the purpose of this research report, the word ‘Complementary Medicine’ will 
be used instead of ‘Non-Allopathic Medicine’. 
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Recognizing the differences between these two systems of health provision is key 
to understanding the issues raised in this research report. 
 
 
1.2 UNDERSTANDING THE TERMINOLOGY 
 
1.2.1 ALLOPATHIC MEDICINE 
 
Allopathic Medicine2 is increasingly the dominant system of health provision in 
western culture, and can be said to reflect cultural attitudes to health and disease.  
Indeed, Allopathic Medicines rely on interpretations of disease and illness related 
to physiological causes, and thus aim to restore healing to the physical body and 
alleviate physical suffering by addressing the biological cause of the illness. 
Allopathic Medicines are characterized by the testing, measurement and scientific 
observation of an illness (Gilbert et al., 1996:50), and have come to be largely 
synonymous with the notion of a scientific approach or method. This may be taken 
to refer to the practice of “accurate observations, arranging the facts in some 
orderly manner to determine relationships and drawing conclusions” (Stiles, 
1942:13).  
 
As defined by the Medicines Act (1965:3), Allopathic Medicines refer to “any 
substance or mixture of substances used or purporting to be suitable for use or 
manufactured or sold for use in a) The diagnosis, treatment, mitigation, 
modification or prevention of disease, abnormal physical or mental state or the 
symptoms thereof in man; or restoring, correcting or modifying any somatic or 
psychic or organic function in man, and includes any veterinary medicine”. In this 
way, it may be said that Allopathic Medicines focus on identifying active 
compounds to treat somatic causes of diseases. 
 
What is evident from this definition is the clear link between the active compound 
and the disease/symptom it is designed to treat. Understanding Allopathic 
Medicines also requires recognition of the increasingly standardized manner in 
which these active compounds are identified, developed and evaluated. This 
                                            
2
 Also known as Western, Conventional, Orthodox and Mainstream.  
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involves highly routinized laboratory investigation to isolate active compounds and 
identify delivery systems, followed by animal testing and a series of clinical trials. 
This will be discussed in Chapter 3.  
 
1.2.2 COMPLEMENTARY MEDICINE 
 
CMs according to the Cochrane Collaboration cited by Vickers & Zollman 
(1999:693) are “a broad domain of healing resources that encompasses all health 
systems, modalities, and practices and their accompanying theories and beliefs, 
other than intrinsic to the politically dominant health systems of a particular society 
or culture in a given historical period”. It is important to note that this definition – in 
keeping with most general discussions on CMs – do not refer to a specific cultural, 
religious or spiritual practice. Rather, CM can be understood as an umbrella term 
to denote practices of healthcare that stand in contrast to Allopathic Medicines. 
 
CMs are commonly understood to focus on illness prevention and health 
promotion, rather than treating specific diseases. CMs are informed by cultural 
interpretations of disease, health and illness and the medications and practices 
are deeply rooted in specific cultures and are often intertwined with the historical-
religious heritage of these people. Understandably, these vary considerably 
around the globe and are best understood from the specific context in which they 
are practiced. “Other commonly known names for CM are holistic, unconventional, 
natural, unscientific, non-orthodox, folk medicine, ethno medicine, mind-body 
medicine, unproven and non-allopathic” (Ernst & Fugh-Berman, 2002: 140). These 
alternate terms reflect not only the diversity of practices under the CM umbrella, 
but also the conflicting ways in which societies – and Allopathic Medical 
practitioners – view CMs. 
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1.2.3 SUMMARIZING KEY DIFFERENCES 
 
The table below highlights the key differences between the two healthcare 
systems based on existing literature on the issue. 
 
TABLE 1: Key differences between CMs and Allopathic Medicines as identified in 
the literature 
CMs Allopathic Medicines 
It focuses on restoration of health 
(Adams & Jewel, 2007:2). 
It focuses on the cure of diseases 
(Singh, 2010:20). 
CMs proceeds with the notion that 
the mind, body and spirit are one 
(Mason et al., 2002:832). 
Allopathic Medicines proceeds with a 
notion that the mind & body are 
separate entities (Mehta, 2011). 
Treat a person as a whole, 
identifying the underlying causes 
and not simply removing a 
symptom (Adams & Jewel, 2007:2). 
One of the guiding principles of 
Allopathic Medicines is treating or 
destroying a symptom (Siamak & 
Shirazi, 2012:1). 
The patient plays an active role in 
the treatment process (Boon et al., 
2006:25). 
The patient does not play a role in 
the treatment process (Davis-Floyd, 
2001:8). 
Developed by folk knowledge 
(Charlton, 2002:643). 
Based on clinical trials and scientific 
experimentation (Charlton, 
2002:643). 
“CMs use the original substance in 
its entity” (Ribeaux & Spence, 
2001:189). 
“The Allopathic approach separates 
the active ingredients and not use the 
rest” (Ribeaux & Spence, 2001:189). 
"Illness is regarded as a deviation 
from health” (Verhoef&Hilsden, 
1998:319). 
“Health is regarded as a deviance 
from disease” (Verhoef&Hilsden, 
1998:319). 
“Reinforcing self-healing” (Bhika& 
Glynn, 2017:15). 
“ Combating destructive or  
Infective” ( Bhika&  
Glynn, 2017:15). 
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 “Emphasises achieving good 
health. Focuses on lifestyle and 
prevention” (Bhika&Glynn, 
2017:15). 
“Emphasises achieving good  
health. Focuses on lifestyle  
and prevention”(Bhika 
& Glynn, 2017:15). 
 
 
It is quite clear from table 1 that there are fundamental differences between CMs 
and Allopathic Medicines – both in the manner of treatment but also in the 
approach to the concept of health. Complementary health systems are involved in 
treating the person holistically by looking at both the mind, spirit and body while 
the Allopathic systems see the mind, body and spirit as separate entities (Moodley 
et al., 2008:153). Allopathic Medicines treat disease causing entities through 
pharmaceutical interventions, while CMs are concerned with assisting the innate 
healing powers of the body in illness management. In contrast, CMs rely heavily 
on testimonials and traditional use (Charlton, 2002:643).  
 
Allopathic Medicines seeks to treat symptoms and CMs do not intend to directly 
target symptoms in the body. CMs and Allopathic Medicines also come from 
different cultural contexts in which disease and illness are variously interpreted.  
As evident from the table above stands in direct contrast to Allopathic systems.   
The CMs practitioner acts to assist the body in correcting the imbalances that 
contribute to the illness. This stands in direct contrast to Allopathic systems. 
According to (Ernst et al., 2003: 157), complementary interventions are “spiritual 
and social while allopathic interventions are directly measurable”. 
 
The history of Allopathic Medicine regulation also stands in direct contrast to CMs.  
Many CMs have evolved “organically” with the evolution of cultures and spirituality, 
with little in the way of formalized evaluation or regulation.  In contrast, as the 
history of clinical trials attests, the last century has seen the rapid development of 
highly standardized regulatory processes for controlling the development and 
distribution of Allopathic Medicines.   As discussed in section 4.3, this regulation 
has been motivated by a combination of historical, ethical and economic reasons. 
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CMs also tend to emphasize the importance of self-care in the patient as a means 
of promoting the body’s self-healing abilities, rather than focusing on the disease 
itself. The CMs practitioner acts to assist the body in correcting the imbalances 
that contribute to the illness. This, as evident from the evidence above, stands in 
direct contrast to Allopathic systems. As a result, complementary interventions are 
“spiritual and social” while allopathic interventions are directly measurable (Ernst 
et al., 2004: 157). 
 
Because of the highly individualistic interpretation of health, and the assisting role 
that the practitioner plays in health acquisition, it may be suggested that CMs 
focus more on individualized care. In contrast, the focus on disease-causing 
entities and interventions enables Allopathic Medicines to focus on standardized 
and generalizable care based on shared physiology. This raises an important 
question about how they can be brought together under one healthcare regulatory 
umbrella - in S.A. as much as on a global level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   ~ 7 ~ 
 
CHAPTER 2- AIMS, RESEARCH QUESTIONS, OBJECTIVES, METHODS AND 
OUTCOMES 
 
 
2.1 AIMS AND RESEARCH QUESTIONS 
 
The main aim of this research report was to analyse some of the ethical issues 
that arised in the current governance of clinical trials of CMs in S.A and also 
offered some recommendations on how these issues could be addressed. 
 
This research report questioned what areas of current oversight may be 
strengthened in order to maximise the benefits of conducting such clinical trials 
and to minimize the harms arising from them. 
 
2.2 OBJECTIVES 
 
The main objectives of this research was to: 
a. Analyse current oversight of clinical trials in CMs in S.A. 
b. To identify areas where the current legislation is not appropriate to CMs clinical 
trials. 
c. To identify ethical and legal problems that may arise from these regulatory 
insufficiencies. 
d. To offer recommendations on how these issues could be addressed. 
 
2.3 METHODS 
 
This research involved legal and normative research and analysis based on 
desktop and library based research. It was an ethico-legal research report drawing 
from the law and ethical literature relevant to the subject matter. No new data was 
collected or analysed. I employed the typical research methods and standards 
applicable to philosophical research including the interpretation and critical 
analysis of salient texts and the positing and defence of new arguments. My 
critical analyses of relevant texts included the definition and clarification of 
concepts, the identification and criticism of assumptions, the analysis and 
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evaluation of theoretical frameworks, the development and defence of arguments, 
the use of counter-examples, and the articulation of the most plausible 
interpretation of significant concepts found in the sources. 
 
Sources of literature included and were not limited to articles at the University of 
the Witwatersrand University Library, Online Library Sources, Pubmed, Jstor, 
Wiley Science and Google Scholar. 
 
The research did not involve study participants and ethics waiver (attached in 
Appendix A) was granted from the University of the Witwatersrand Human 
Research Ethics Committee (HREC). 
 
2.4 OUTCOMES 
 
Although research has been done on CMs, none has as far as I know have been 
done on ethical challenges faced in clinical trials of CMs in S.A and when I looked 
at other countries little research was done on this topic. 
 
This research report will offer a range of recommendations for improvements in 
running clinical trials of CMs in S.A by having guidelines specifically for clinical 
trials on CMs. The absence of guidelines for clinical trials on CMs affects the 
approval of the clinical trials on CMs because what is applicable to Allopathic 
Medicine cannot be applied to a CM. 
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CHAPTER 3- REGULATING MODERN MEDICINES 
 
 
This chapter outlines the history of clinical trials then the major difficulties 
encountered when applying randomised controlled trial (RCT) methodology to 
CMs clinical trials. It also gives other methods that could be used as alternatives to 
RCTs such as mixed methods studies and observational studies. 
 
3.1 INTRODUCTION 
 
‘Standardization of medicines makes them to conform to a standard, consistent 
and also uniform. Standardization also ensures that the safety and efficacy are 
maximized (Folashade, Omoregie & Ochugu, 2012:102). According to Carissa & 
Califf (2016:213) “the regulation and standardization of medicines are important 
because it promotes and protects the public health by ensuring that: 
 Medicines are of the required quality, safety and efficacy3; 
 Medicines are appropriately manufactured, stored, distributed and 
dispensed;  
 Illegal manufacturing and trade are detected and adequately sanctioned;  
 Health professionals and patients have the necessary information to enable 
them to use medicines rationally;  
 Promotion and adverting are fair, balanced and aimed at rational drug use;  
 Access to medicines is not hindered by unjustified regulatory work”. 
 
Issues on standardization are fundamental to modern understandings of just 
healthcare provision. 
 
 
 
 
 
                                            
3Safety means tolerability and side effects while efficacy refers to whether or not it 
works. 
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3.2 HISTORY OF CLINICAL TRIALS  
 
In Allopathic healthcare, clinical trials are widely agreed to be the best current form 
of standardization. Nonetheless, the recent attention paid to clinical trials does not 
denote new practices per se. Indeed, clinical research on human subjects dates 
back several hundred years, with the first documented controlled clinical trial was 
conducted in 1747 on 12 sailors with scurvy by Dr. James Lind. Through this trial 
he showed that citrus fruits such as lemon and oranges cured scurvy (Chalmers, 
1981:326).  
 
The first publicized blinded placebo-controlled randomized clinical trial was in 1946 
which was performed by the MRC (Medical Research Council) in the UK(Jenkins 
& Hubbard, 1991: 228). This trial was reporting the effect of streptomycin on 
tuberculosis, and was the first one to randomly assign patients to experimental 
and control groups. This trial represented a significant advance in clinical trials 
methodology and contained features which remain fundamental to the design of 
clinical trials today. In the 20th and 21st century clinical trials have increasingly 
become the legally accepted mode of proving medicinal efficacy and safety, and 
are intricately connected to legislative and policy measures governing health.  
 
3.3 THE MODERN CLINICAL TRIAL 
 
According to South African Good Clinical Practice Guidelines (SAGCP)(2006:87), 
a clinical trial refers to “any investigation in human participants (including patients 
and other volunteers) intended to discover or verify the clinical, pharmacological 
and/or other pharmacodynamic effects of an investigational product(s), and/or to 
identify any adverse reactions to an investigational product(s), and/or to study 
absorption, distribution, metabolism, and excretion of an investigational product(s) 
with the object of ascertaining their safety and/or efficacy”4. 
 
Each clinical trial follows a protocol that defines the aim or rationale of the trial, 
defines the objectives, the design and methods used in the trial or the study 
(Hassim et al., 2007:390). Clinical trials in humans are conducted into four phases. 
                                            
4For the purpose of this research report, that is the definition that will be used. 
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Phase 1 involves testing an active ingredient on a small number between 50-100 
healthy participants or patients. The purpose of phase 1 is to evaluate the safety of 
the active ingredient, to determine the safe or acceptable dosage and also to 
identify potential side effects.  
 
Phase 2 trials involve administering the medicine to a larger number of patients 
between 100 and 300 who currently experience the condition or disease to which 
the active ingredient is directed. This phase evaluates the safety and efficacy of 
the active ingredient (Hassim et al., 2007:390). Only once phase 2 evidence is 
available and has been assessed according to stringent standards (usually the 
MCC), permission will be granted to continue with phase 3.  
 
Phase 3 involves a large number of people (500-1500 volunteers). Phase 3 
evaluates the effectiveness of the active ingredient and the prevalence and types 
of side effects that it may cause. The medicine might be compared with currently 
used treatments on the market to determine its potential as an improved means of 
health provision. The final phase of studies is phase 4 which is the post-marketing 
surveillance (Gupta & Kohli, 2006:191). It is done after the medicine is registered. 
Its purpose is to collect additional information after the product is approved and 
marketed or to compare the medicine’s efficacy with those of other medicines. 
 
3.4 IMPORTANT ELEMENTS OF MODERN CLINICAL TRIALS 
 
A randomized clinical trial (RCT) or randomized controlled trial is considered the 
gold standard of Allopathic Medicines research (Akobeng, 2008: 278). These 
assess the efficacy of the intervention in human beings by comparing the 
intervention to a control in groups that have been randomly assigned (Levin, 
2007:22). Rajagopalan et al., (2013:32) suggests that RCTs are effective because 
they are “most like an experiment, it is the only effective method known to control 
selection bias, it is able to directly eliminate risk and it also allows comparison of 
multiple outcomes”. In this way, RCTs cleave very strongly to current 
interpretations of the scientific method, and western science practices. 
 
There are three important elements or features for RCTs (Grady, 2008:23), the 
first of which is randomization or random allocation. Randomization occurs when 
 
  
   ~ 12 ~ 
two or more groups are compared and all participants have the same chance of 
either being assigned to the treatment or placebo (Iyioha, 2011:40). It is a chance 
rather than a choice and allocation is not determined by the investigators but 
rather by statistics.  
 
The basic motivation for randomization is to prevent or eliminate selection bias, 
increases the internal validity (repeatability) and ensures that all variables have the 
same effect on all groups. Randomization also balances arms with respect to the 
known and unknown variables (Pihlstrom et al., 2000:16). Ones allocated to a 
group, participants will be asked to remain in it until the end of the trial.  
 
The second critical feature of RCTs is blinding (Karanicolas, 2010:345), meaning 
that study participants, researchers and health care professionals do not know 
who is in the experimental group and who is in the control group. Blinding is a key 
marker of internal validity, as it reduces the possibility of bias – from the 
researcher, but also (through psycho symptomatic reactions) the participant. Zick 
et al., (2005:101) suggests that “blinding is an important method to also ensure the 
quality of a clinical trial. It improves participant compliance and retention in clinical 
trials. Lack of blinding usually leads to bias”.  
 
Blinding can either be single, double-blind or triple-blinded (Akobeng, 2005:842). 
Single blind is an RCT in which one group of individuals involved in the trial does 
not know the identity of the intervention that is given to each participant. Usually, it 
is the participants or the investigators assessing the outcomes who do not know 
the identity of the interventions.  
 
RCTs are usually conducted double blinded, where neither the trial participants 
nor the investigators or people collecting the outcome data are aware of any 
assigned intervention. For double blinding to be successful, the interventions must 
be indistinguishable – visually, in how they are administered, and how they 
taste/smell/feel - to both the participant and the investigator assessing the 
outcomes. Typically, the interventions are known simply as A or B and are 
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otherwise identical (Walker & Anderson, 1999:1616). Triple blind is when 
participants, the investigator giving the intervention and the one who evaluates it 
are all blinded. Triple blinding happens rarely. 
 
The third element in an RCT is the presence of either an active control or a 
placebo that is administered to half the participants5. Active controls represent an 
existing treatment for the condition that is currently on the market. The existence 
of a control group enables the efficacy of the experimental drug to be effectively 
assessed. It must be noted that the use of a placebo (as a treatment without active 
ingredients) in clinical trials continues to arouse controversy – particularly in phase 
2 and 3 trials where it results in sick patients not receiving treatment for the 
duration of the trial. According to Grace (2006: 58) using placebo in clinical trials is 
more about “deceiving patients and this is unethical as deceiving patients 
constitute a failure to respect their rights to make informed decisions thus a breach 
of ethical practice”.  
 
Clinical trials have developed synergistically with Allopathic Medicines, and may 
be said to closely reflect the perspectives of this system. Because of this, many of 
the key points – such as blinding, randomization and independent verification – 
strongly reflect the interpretation of disease as caused by biological entities. 
 
3.5 REGULATING CMs WITH CLINICAL TRIALS: AN UNEASY FIT? 
 
Most governments rely heavily on clinical trials for regulation and legislation as 
these trials offer evidence for or against efficacy and safety. This “objective” 
information makes it easy to legislate for or against the introduction of medicines 
into healthcare provision. 
 
One could thus argue that to incorporate CMs into legislated healthcare provision 
it is feasible to assume that they should also be tested through clinical trials. 
                                            
5Placebo is a pharmacologically inactive agent that investigators administer to 
participants in the control group. 
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Nonetheless, as evidenced in table 1, the manifold differences between these two 
systems of health provision must give pause for thought. How can systems of 
verification that focus on active ingredients and biological causes for illnesses be 
used to assess the efficacy of holistic health interventions?. 
 
Indeed, many CMs practitioners or proponents of CMs have argued this point - 
that CMs should be exempted from the requirements of RCTs because the 
designs of RCTs are inappropriate to fit many forms of CMs therapies (Iyioha, 
2011:2). They also strongly suggest that any results of testing CMs with RCTs 
would be misleading due to the impropriety of the mode of evaluation. Some argue 
that CMs have been practiced for so many years and there is anecdotal/traditional 
evidence so they do not need to be subjected to RCTs. These concerns are more 
fully discussed in below by focusing on the main elements of RCTs. 
 
3.5.1 RANDOMISATION 
 
As discussed in section 3.4, the randomization of trial participants to study or 
control groups is a key element in RCT design. This minimizes the possibility of 
selection, allocation, assessment and publication bias (Akobeng, 2008:841). As is 
suggested by the term, true randomization can only occur when all participants 
submit to being statistically divided into equal groups.  
 
In CMs clinical trials such randomization might be hindered by the patient’s strong 
preferences for a CM or practitioner’s preference of one treatment over another 
making them unwilling to participate in studies where they are allocated to the 
placebo or control group. Randomisation might also affect the treatment effect 
(Verhoef et al., 2005:207). Unlike Allopathic Medicines, where the patient does not 
usually take part in the treatment process as indicated in Table 1, for CMs the  
active involvement of the patient in the healing process is key to the intervention’s 
success. Thus, as Hamre et al., (2009:52) suggested, “the doctor-patient 
relationship in CMs therapies is very integral and it is disturbed by randomization”, 
as could be the efficacy of the intervention.  
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3.5.2 BLINDING 
 
As already mentioned in section 3.4, blinding prevents bias amongst researchers 
and participants. Blinding is an integral part of RCTs however how it can be 
achieved for many CMs is difficult to understand. Indeed, such blinding may be 
impractical or impossible as the practitioner and patient play integral roles in the 
healing process (Richardson, 2000:400).  
 
Another key problem occurs through the need to have indistinguishable active and 
control treatments. According to Turner (2009:413), “the distinctive taste or smell 
of some herbal and alternative therapies poses a significant challenge to the 
appropriate blinding of study treatments”. Sharma (et al., 2010:277) stated that in 
Ayurvedic medicines it is always “difficult, impracticable or sometimes impossible 
to have active and control groups with identical colour, smell and taste. Indeed, it 
would be difficult to mimic the strong smell of ginger or garlic within a preparation 
(Bansal et al., 2010:18), or to administer a placebo massage or meditation.  
 
3.5.3 ACTIVE CONTROL GROUP OR PLACEBO  
 
The problems of blinding are similarly related to the difficulties of identifying 
appropriate placebo control group6. In acupuncture treatments7 for example, the 
patient would often be able to tell if they are receiving the control and the 
experimental by the way the needles are inserted.  
 
Moreover, as CM treatments often specialized for each patient rather than 
standardized to treat a hypothesized disease entity, finding a single control that 
could be effectively administered to a group of patients is difficult to imagine. 
Finally, it is not always clear whether interactions exist between herbal medicine 
and other medicinal products or substances like alcohol, caffeine, tobacco, 
nicotine or with diet. This also creates huge problems for the inclusion and 
exclusion criteria for clinical trials. 
 
                                            
6 Placebo control is a comparable therapy. 
7 In this research report, Acupuncture will be used as an example. 
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3.5.4 STANDARDISATION 
 
It is also difficult to standardize the dosage of CMs in RCTs due to the lack of 
information about how (and why) treatments are effective. According to Verhoef et 
al., (2002: 276), the other reason it is so difficult to standardize CMs is that “there 
are wide variations in practice” that reflect the individual practitioner and their 
contextual training. As such, it would be very difficult to envisage how multi-site, 
multi-practitioner standardization could be achieved in CM clinical trials. 
 
There are also a number of other issues to consider that relate to mind, spirit and 
body theories embraced by many CMs. This includes the importance of personal 
beliefs in CMs use, the involvement of the practitioner in the CM treatment 
experience, and the personalization of CM practitioning that may lead to a lack of 
standardization of CM practices (Mason et al., 2002:833).  
 
Commercially produced CMs also vary according to manufacturers which make it 
difficult to standardize it. CMs are composed of many active components which 
are not yet identified and this makes standardization challenging. Other practical 
problems with CMs clinical trials as discussed by Osemene, Elujoba & Ilori (2011: 
281) are “issues of dosage specifications, lack of proof of their efficacy, safety, 
proper problems, appropriateness of their degree or level of hygiene and cost of 
their production”.  
 
CMs such as Traditional Chinese Medicine (TCM) present further challenges, as 
they focus on symptom-complexes rather than individual diseases. These 
interventions describe the functioning of the whole body at a particular time and a 
particular stage of an illness. Because a symptom-complex is virtually unique to a 
particular patient, it is not possible to group patients for a study in a randomized 
trial as it is in Allopathic Medicines. Moreover, symptom-complexes are different 
for each patient, so the treatments of them are highly variably so. Walji & Boon 
(2006: 92) also stated that “RCTs cannot be used to examine the effectiveness of 
CMs due to conflicting theories of disease, lack of agreement about diagnostic 
criteria, contrasting view about the therapeutic process and different theories of 
causation”.  
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3.5.5 PROPOSED ALTERNATIVE TO RANDOMISED CONTROLLED 
CLINICAL TRIALS 
 
Envisioning effective RCTs for CMs is thus difficult, and there has been 
considerable discussion about the possible establishment of alternative methods 
of verification. Verhoef et al., (2005: 209), for example, proposed regulated 
individual observational studies as a possible alternative. Observational case 
studies are often suggested as an alternative to RCTs.  Verhoef suggested that 
(2005: 209) “Observational studies are even less complex, less expensive to 
operate and they have strong external validity”. Benson & Arthur (2000:1878) also 
stated that “observational studies have greater timeliness, lower cost and a 
broader range of patients than the RCTs”.  
 
There are three types of observational studies, namely case control studies, cross-
sectional studies and retrospective/prospective cohort studies (Mariani& Pego-
Fernades, 2014:1). While “RCTs have specific inclusion and exclusion criteria that 
are often restrictive, observational studies apply to a much broader population and 
are frequently even population-based” (Hannan, 2008:214). In observational 
studies, the population is not highly selective or there is no limit to the number of 
participants that can be included while in RCTs the population size is highly 
restrictive. According to Yang et al., (2010:S5) the restricted inclusion and 
exclusion in RCTs mean “that the type of patient enrolled into a particular trial 
bears little resemblance to the typical patient seen in the clinic”. 
 
According to Yang et al., (2010:S4) cross-sectional studies “provide information on 
the prevalence of a particular condition at a single time point. These studies take a 
form of questionnaires and thus can be prone to responder bias in those 
individuals who give their time to respond to a questionnaire”. The main 
advantages of this study are that “As there is no follow up, less resources are 
required to run the study and they are quick” (Mann, 2003:57). 
 
Case control studies compare groups retrospectively and are often used to 
generate hypotheses. “They aim to identify predictors of a particular outcome. The 
difficulty with case control studies is ensuring that cases and controls are a 
representative sample from the same source population. These studies can be 
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affected by recall bias” (Yang et al., 2010:S4). The main advantages of this study 
are that “it “Relatively quick to conduct and also inexpensive” (Song& Chung, 
2010:17). 
 
Cohort studies “takes a group of individuals who share a common characteristics 
(for example, a particular treatment, date of birth, or who have a particular 
disease. These studies are useful for identifying the incidence of a particular 
outcome over time” (Yang et al., 2010: S4). The main advantages of this study are 
that “it can examine various outcome variables and it is also much cheaper” 
(Mann, 2003:55). 
 
According to Wardle & Roseen (2014: 144) “case reports continue to capture and 
describe important patient-centred clinical insights that may inform the 
individualised nature of contemporary patient care. Case reports can generate 
hypotheses for future clinical studies and also point to unknown risks or 
demonstrate regulatory or practice failures”.  Case reports can also identify new 
treatment options. The main advantages of case reports are that “answers can be 
obtained rapidly and they are inexpensive” (Manja & Lakshminrusimha, 2014:3). 
 
Verhoef et al., (2005: 209) also proposed alternatives such as mixed methods 
research and appropriate outcome research. Mixed methods research “combines 
both the quantitative and qualitative research methods. Appropriate outcome 
measures the expected outcome of CMs interventions and practitioner” (Verhoef 
et al., 2005: 209). The values and beliefs of the patients are more easily captured 
using mixed methods research. 
 
Qualitative research can assist in understanding the meaning of an intervention to 
patients as well as patient’s beliefs about the treatment and expectations of the 
outcome (Verhoef et al., 2002:275). Both qualitative and quantitative researches 
are used to obtain a specific research question. This method also increases the 
internal validity of the research. 
 
Pragmatic RCTs might also be applicable to CMs therapies as they take patient 
preferences into account. According to Patsopoulos (2011: 218) “The pragmatic 
trial is designed to test interventions in the full spectrum of everyday clinical 
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settings in order to maximize applicability and generalizability. The research 
question under investigation is whether an intervention actually works in real life”. 
Pragmatic RCTs are designed to also ensure that external validity is taken into 
consideration. According to Williams et al., (2015: 1) “pragmatic clinical trials seek 
to answer important questions that are applicable to everyday clinical practice”. 
 
Nonetheless, such suggestions have not met with much favour in healthcare policy 
and legislative communities – particularly as RCTs have become such a 
fundamental means of assessing medical efficacy. There have been numerous 
articles published by different authors who outlined the limitations of alternative 
methods such as pragmatic trials, mixed methods and observational studies. In 
one of their articles, Ernst & Canter (2005: 203) stated that pragmatic trials are not 
the best tools that could be used as their “results are frequently next to 
meaningless”. Another limitation of pragmatic trials is the fact that results that are 
used in S.A can never be applicable in the U.S.A for example. Even if it is the 
same country, clinical settings varies according to sites so the results can never be 
guaranteed. 
 
The disadvantage of observational studies is that because of its lack of 
randomization there is a strong likehood of selection bias which makes this 
method one of the unfavourable methods to RCTs. According to Tariq & 
Woodman (2010: 6) using mixed methods is also problematic as “a quantitative 
and qualitative method belongs to a separate paradigm. Combining this two 
methods can be time consuming and requires experience and skills in both 
qualitative and quantitative methods”. 
 
In conclusion, this chapter highlighted main issues encountered when using the 
RCT method for CMs clinical trials. It also offered alternatives which could be used 
in place of RCTs. The next chapter will look more deeply into the deficiencies of 
the current system, SAGCP when applied to CMs clinical trials. 
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CHAPTER 4-STANDARDIZATION AND REGULATION OF COMPLEMENTARY 
MEDICINES IN SOUTH AFRICA 
 
 
4.1 INTRODUCTION 
 
The previous chapter provided a short history and evolution of clinical trials. It also 
highlighted issues which are currently faced when regulating CMs with clinical 
trials. In this chapter, I will give an overview of this and a critique of current 
issues.8 
 
4.2 OTHER REGULATORY AGENCIES GUIDELINES AND CURRENT 
ATTEMPTS TO ADDRESS CLINICAL TRIALS OF CMs 
 
Table 2 in the next page summarizes the guidelines for clinical trials in 
CMs/Traditional Medicine/Herbal Medicine of the different regulatory agencies. 
Clinical trials are necessary to test the efficacy and safety of those CMs which are 
on the market and those that are still going to be on the market. The WHO 
Guidelines for clinical trials of Traditional Medicines and the WHO Guidelines for 
Clinical Study of Traditional Medicines in the WHO Africa Region could be used as 
reference guidelines to draft the South African guidelines for clinical trials of CMs 
or could be incorporated into the current SAGCP. 
 
The WHO guidelines “focus on the current major debates on safety and efficacy of 
traditional medicine and are intended to raise and answer some challenging 
questions. These guidelines present some national regulations for the evaluation 
of herbal medicine and also recommend new approaches for carrying out clinical 
                                            
8 For this research report, we make no distinction between OTC (Over the 
Counter) and prescription drugs. This research report works on the thought that all 
drugs should undergo testing before they are put on the market or released. 
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research. These guidelines will achieve their purposes of improving the quality and 
value of research in traditional medicine” (WHO, 2000: vi). “The Australian 
regulatory guidelines for Complementary Medicines provides information for 
manufacturers, sponsors, healthcare professionals and the general public on the 
regulation of Complementary Medicines in Australia” (ARGCM, 2016:11).  
 
Table 2: Regulatory Guidelines for clinical trials of CMs/Traditional 
Medicines and/ or Herbal Medicines in other countries of the world. 
Requirements for the 
clinical trials of  
CMs/Traditional 
Medicine or Herbal 
medicine 
WHO General Guidelines 
For Methodologies on 
Research and Evaluation 
of Traditional Medicine 
Australian Guidelines 
for CMs(ARGCM) 
Botanical Drug 
Development Guidance 
for Industry(FDA) 
MCC(SAGCP) 
 
 
 
 
 
 
Traditional Use It is considered in the 
evaluation of safety and 
efficacy(WHO,2000:24) 
Use of Traditional 
Medicine must be well 
established and widely 
acknowledged (ARGCM, 
2016:115). 
 
 
 
Traditional use is not 
considered in the 
evaluation of safety and 
efficacy(FDA,2016:28) 
Traditional use 
is not 
considered in 
the evaluation 
of safety and 
efficacy. 
Safety “Documentation of a long 
period of use should be 
taken into consideration 
when evaluating safety” 
(WHO, 2000:24). “Toxicity 
studies should be performed 
when there is doubt about 
the safety” (WHO, 2000:6). 
“It may be established 
by detailed reference to 
the published literature 
and/or the submission of 
original data” (ARGCM, 
2016:115). 
Requirements are the 
same as for Allopathic 
Medicines(FDA,2016:28) 
Requirements 
are the same 
as for 
Allopathic 
Medicines. 
Efficacy WHO (2000:25) “Where 
traditional use has not been 
established, appropriate 
clinical evidence should be 
required” to evaluate 
efficacy. 
“Safety may be 
established by detailed 
reference to the 
published literature” 
(ARGCM, 2016:114) 
Requirements are the 
same as for Allopathic 
Medicines( FDA,2016:28) 
Requirements 
are the same 
as for 
Allopathic 
Medicines. 
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4.3CURRENT PROCESS OF CMs REGISTRATION IN SOUTH AFRICA 
 
As mentioned already, “the WHO estimates that 80% of the world’s population use 
CMs as their primary source of healthcare and similar figures have been reported 
in the South African population”(Siegfried & Hughes, 2012: 2). Nonetheless, until 
1982 there was no definition of CMs in S.A and the types, extent and 
administration of CMs within communities was poorly documented.  
 
The current definition of CM in S.A9 according to the Medicines Act “ means any 
substance or mixture that a) originates from plants, fungi, algae, seaweeds, 
lichens, minerals or animals or other substance as determined by Council; b) is 
used or purporting to be suitable for use or manufactured or sold for use, i) in 
maintaining, complementing, or assisting the innate healing power or physical or 
mental state, or ii)to diagnose, treat, mitigate, modify, alleviate or prevent disease 
or illness or the symptoms or signs thereof or abnormal physical or mental state, of 
a human being or animal ; c) is used i)as a health supplement, or ii) accordance 
with those disciplines as determined by Council or d)is declared by the Minister, on 
recommendation by the Council, by notice in the Gazette to be a Complementary 
Medicine”. Interestingly, however, this remains a proposed definition and still 
needs to be formally ratified. 
 
WHO defines traditional medicine as quoted by as (Hassim et al.,2007:202) 
“diverse health practices, approaches, knowledge and beliefs incorporating plant, 
animal and/or mineral based medicines, spiritual therapies, manual techniques 
and exercises applied singularly or in combination to maintain well-being, as well 
as to treat, diagnose or prevent illness”. 
 
                                            
9Proposed Amendments to General Regulations made in terms of the Medicines 
and Related Control Act No 101 of 1965(25 July 2016).Proposed addition of 
Health Supplements is under review. To effectively regulate medicines in S.A, 
CMs have been separated from the African Traditional Medicines (ATM). The term 
CM is used interchangeably with Traditional Medicine (TM) in some countries but 
not in S.A. For the purpose of this research this will be the definition of CM that will 
be used. 
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Similarly, until November 2013 there was no legislative framework for the control 
of CMs (manufacturing, distribution and use) within SA. This was due to the fact 
that there was no regulatory framework in place such as guidelines and 
regulations specifically for CMs. On the 22nd February 2002, the National 
Department of Health (NDOH) through Medicines Control Council (MCC) 
published a Call Up Notice10 which requested importers, consumers, wholesalers, 
retailers and manufacturers of CMs to submit limited information for audit 
purposes only not for registration purposes for products already on or about to 
enter the market at that time for a period of 6 months.  
 
The purpose of the Call Up Notice was to see which products are on the market 
and also which are entering the market but instead this Call Up Notice caused so 
much confusion amongst the importers of CMs and the industry as many thought 
this was the registration process. This process was very flawed as it did not ask 
many questions regarding the safety, efficacy and quality of the product. 
 
Currently, CMs applications are submitted on a ZA-CTD Form11. The application 
form is obtainable from the MCC website where all the information pertaining to 
the registration of medicines including guidelines and fees are also available. This 
call for registration thus places the MCC under obligation to evaluate and 
pronounce on the quality, safety and efficacy of CMs. In so doing, it has become 
necessary to subject CMs to a form of independent, reproducible and verifiable 
system of evaluation for all CMs.   
 
Currently, CMs in S.A are divided into discipline specific and health supplements. 
Disciplines specific CMs are “Aromatherapy, Ayurveda, Homeopathy, TCM, Unani 
Tibb Medicine and Western Herbal Medicine” (Fourie, Oosthuizen& Du Toit: 2017: 
484). Types of health supplements are probiotics, prebiotics, vitamins, minerals, 
amino acids, animal extracts, carotenoids, bioflavonoids, amino saccharides, 
saccharides and enzymes.  
 
                                            
10 Call Up Notice No R204, Regulation Gazette No 7282. 
11 CTD stands for common technical document. 
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Clinical trials have been proposed as the easiest way in which to address safety 
and efficacy of medicines, however – as outlined above – this is deeply 
problematic. It is further problematic due to the fact that there are no guidelines at 
the moment specifically addressing clinical trials in CMs and the SAGCP 
guidelines used are not compatible with CMs clinical trials. There is thus a tension 
between the need for regulation and perpetuating a flawed system of evaluation. 
 
4.4 SUBJECTING CMs TO CLINICAL TRIALS IN S.A: CURRENT 
REGULATIONS 
 
The current legislative regulatory framework for the control of clinical trials in S.A is 
the SAGCP guidelines which were published in 2000 and updated in 2006. These 
guidelines are guaranteed by the South African National Health Act of 200312 and 
are similar to the International Conference on Harmonization Good Clinical 
Practice (ICH-GCP). These guidelines – unsurprisingly – are designed for the 
regulation of RCTs on Allopathic Medicines. They thus emphasize the norms of 
clinical trials such as double blinding, randomization and standardization.  
 
The SAGCP guidelines are intended to ensure that the clinical data are credible. It 
also protects the rights, safety and well-being of trial participants. A clinical trial in 
S.A may not commence until approval by both the MCC and the local ethics 
committee is obtained. The second guideline which is referred to with regard to 
any research in human participant in S.A is the Research Ethics Guidelines which 
was updated in 2015 by the National Department of Health (NDOH13). 
 
At present, there are no guidelines or any legislation framework in place 
specifically for clinical trials on CMs in S.A. Nonetheless, the SAGCP guidelines 
(2006: 12) stated that in the absence of guidelines for CMs the SAGCP 
                                            
12 Section 90 of the National Health Act, Act No 61 of 2003. 
13 Ethics in Health Research: Principles, Structures and Process. Department of 
Health. Pretoria. 2015.2nd Edition. 
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guidelines14 can be used to guide any research on human participants. As the 
SAGCP guidelines are designed for use in clinical trials for Allopathic Medicines, 
their use thus further complicates an existing problem. Moreover, the SAGCP 
guidelines do not engage with alternative ways of assessing.  
 
Indeed, the guidelines do not addressed issues such as criteria for standardization 
of CMs or take into account the individuality of each CM therapies. As already 
mentioned in chapter 3, randomization is difficult or challenging for some CMs 
clinical trials and in the SAGCP guidelines there is no mention of how best to solve 
this problem. WHO guidelines (2000: 14) clearly stated that “where randomization 
is impossible, the best way to solve that problem is by proper selection of the 
control treatments”. WHO guidelines for Clinical Study of Traditional Medicines in 
the WHO African Region stated that “pseudo-randomization method may be 
adopted by using block randomization where a balance will be achieved for every 
sixth or patient”. The SAGCP guidelines (2006: 53) only mentioned that “in the 
case of randomisation of participants, the procedure must be documented”.  
 
Furthermore, there is no mention of what should be done in cases where it is 
difficult to blind in the SAGCP guidelines. As mentioned in the previous chapter, 
blinding is difficult in clinical trials of CMs. WHO guidelines (2000: 15) stated that 
“it is important to note in the evaluation of study that blinding was difficult”. There is 
also no mention of how CMs safety can be assessed and supported in the SAGCP 
guidelines.  
 
The WHO guidelines (2000: 24), FDA: Guidance for Industry: Botanical Drug 
Products(2016:15) and Australian Regulatory guidelines for CMs (2016: 114) 
clearly mentioned that the safety of CMs, botanical drugs or traditional medicines 
can be supported by the traditional use or long period of use and also published 
literature/peer reviewed scientific papers and bibliographical evidence from books 
and pharmacopoeias, must be presented along with the application to prove 
traditional use or long period of use. The Australian Regulatory guidelines for CMs 
                                            
14 There are other important documents dealing with various aspects of CMs, such 
as Intellectual Property Systems (IPs) but they are beyond the scope of this 
research report to discuss in detail. 
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(2016: 75) further states that when traditional used to demonstrate safety you also 
need to look at certain number of people who used those CMs. It further states 
(2016: 163) that “you must clearly indicate whether the substance under review is 
the same as that used traditionally, that is: the same plant part, preparation, 
dosage and dosage form”. 
 
The SAGCP guidelines also do not explain about what happens if there is no 
documentation of traditional use. The WHO guidelines (2000: 6) clearly states that 
“if there is no documentation of traditional use then toxicology should be 
performed”. There is no way in the SAGCP guidelines whether it mentions what 
kind of information is needed to support claims based on evidence of traditional 
use15 and also the scientific use of a CMs. The WHO guidelines make guidance 
with the type of information which must be submitted for claims on both the 
traditional use and also scientific evidence. FDA guidelines for Industry: Botanical 
Drug Products (2016:15) clearly states that “if there are no prior human experience 
or known safety issues, additional early-phase clinical data should be provided 
before initiating larger-scale, late phase clinical studies. 
 
The SAGCP guidelines urgently need to be revised, as to make clinical trial 
guidelines for CMs acceptable as part of good clinical governance.  This requires 
considerable further research and investigation.  First and foremost, there is the 
need that “clinical research aimed at evaluating traditional medicine should 
incorporate research designs, such as randomized controlled trials or 
observational studies” (WHO, 2000: 11).  Further research is also necessary on 
the efficacy on other means of evaluation, such as mixed methods research, 
observational studies, case studies and case reports. 
 
The development of SAGCP oversight for CMs would also benefit from the 
experiences of other regulatory agencies such as WHO, FDA and TGA.  These 
have all recently developed guidelines for clinical trials in herbal medicines.  While, 
                                            
15 According to WHO (2000:41)“traditional use refers to documentary evidence 
that a substance has been used over three or more generations of recorded use 
for a specific health related or medicinal purpose”. 
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of course, the unaltered re-use of these guidelines is inappropriate, an in depth 
analysis of them could add value to the SAGCP.   
 
In conclusion, having looked at SAGCP guidelines, what it overlooks in terms of 
CM clinical trials, the current problems that are faced can be summarized as 
follows: 
i. The government is under obligation to provide guidelines for clinical trials of 
CMs and to regulate CMs clinical trials.  
ii. SAGCP guidelines developed for Allopathic Medicines are problematic for CMs 
clinical trials. 
iii. There is no inclusion of other alternative methods such as observational 
studies. 
 
The next chapter will examine some of the ethical issues that arise when 
incompatible regulatory policies, such as the SAGCP, are used to regulate CM 
clinical trials. It will focus on a range of different issues relating to the participant, 
the practitioner, but also the scientific and medical professions more broadly. 
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CHAPTER 5- ETHICAL PROBLEMS WITH CONDUCTING CLINICAL TRIALS 
WITH COMPLEMENTARY MEDICINES: ACCORDING TO THE SOUTH 
AFRICAN REGULATIONS 
 
 
In section 4.4 of the last chapter, I looked at problems encountered when applying 
SAGCP guidelines to CMs clinical trials. In this chapter, I will be looking and 
discussing the ethical issues encountered in the absence of guidelines for clinical 
trials of CMs or the ethical issues that arises when SAGCP guidelines are used for 
clinical trials of CMs. The recognition of these ethical issues makes the formation 
of new regulation for CM clinical trials not only desirability, but an ethical necessity.  
Unpacking these issues clearly illustrates the impropriety of continuing with the 
current status quo, and the maleficence of the government perpetuating of a 
flawed system of regulation. Such issues to be considered include the failure of 
the government to protect the public, the high costs of conducting RCTs with few 
viable returns, and the burden of unnecessary participant involvement.  
 
This chapter focused on participant-related issues due to the need to limit the 
scope of the research report, but other key issues will deserve attention in the 
future, such as issues relating to liability, ownership and IP, and public/private 
responsibility. The chapter focused on participant-related issues as these have the 
potential to cause the most direct harms if not protected in CM clinical trials. These 
concerns map well on to broader discussions on RCTs and therefore give 
considerable scope for evaluating harms/benefits of CM RCTs against a highly 
examined backdrop of patient protection in RCTs more generally. 
 
The chapter also focused on issues of governance and policy for example in page 
32 where it states that flawed or incompatible guidelines affect issues of informed 
consent. In page 31 as well it shows that the lack of guidelines for CMs clinical 
trials also leads to poor regulation and this place RECs in a difficult position. 
These issues are all related to policy and governance issues. 
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5.1. CONSIDERING THE SCIENTIFIC VALIDITY FOR CMs CLINICAL TRIALS 
 
Validity in RCTs demands sound scientific practices to ensure the accuracy of 
scientific findings so that the study yields reliable information. “Scientific validity 
relies on internationally accepted principles of research practice and should be 
considered an ethical requirement of any research or a prior condition for any 
ethical research”(Freedman 1987: 7). This ethical imperative stems from a number 
of different observations relating to why it was appropriate to conduct the study.  
 
First, “the ethical justification of scientific validity for any clinical trial/s relies on the 
principle of the avoidance of exploitation of participants” (Naidoo; 2014: 37). At its 
most primary level, this refers to the inacceptability of participants assuming the 
risks of any RCT if the trial itself cannot produce useful results. It therefore follows 
that a study can only be ethical if the methods employed can be feasibly assumed 
to yield scientifically valid results. 
 
Scientific validity consists of two aspects the external and internal validity. 
According to Tilburt & Kaptchuk (2008: 596) internal validity means that “the 
research must reliably test hypothesized relationships between an intervention and 
an outcome under controlled conditions. Internal validity tries to answer the 
research question”. 
 
Chapter 3 stated that blinding enhances and protects internal validity and also 
assists in avoiding bias. Nonetheless, as discussed, blinding is difficult or 
impossible in some CMs clinical trials because the practitioner is an important part 
of the intervention. Internal validity is dependent on appropriate randomization and 
blinding. CMs clinical trials lack internal validity as randomization and blinding are 
at times difficult to achieve. The unique characteristics of CMs also make it difficult 
to obtain internal validity. RCTs also have higher internal validity and it is difficult 
or impossible to conduct a RCTs of CMs. 
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External validity16 is defined by (Millard et al., 2014: 2) as “the extent to which 
results can be generalized to other circumstances”. In order for the research to be 
of any use, it must be possible to generalize the results. External validity is often 
difficult for some CMs clinical trials because it might be difficult to generalize the 
results from a formal and structured clinical trial as it is done in Allopathic 
Medicines. The current SAGCP guidelines undermine scientific validity because 
the guidelines are specifically for Allopathic Medicines as already discussed in the 
previous chapter and not for CMs and it is inevitable that when they are used for 
CMs clinical trials they will be found not to be suitable. The SAGCP requirement 
for CM clinical trials must cause concern as to what types of information are being 
generated by these trials as some of those trials are not providing useful 
information.   
 
Some CMs clinical trials also lack external validity due to lack of strict 
standardization as discussed in chapter 3. RCT usually provides valid and reliable 
results to be used in clinical research but in CMs clinical trials they are at times 
impossible or difficult to conduct as already discussed in the previous chapter. 
CMs clinical trials often lack randomization or it is difficult to randomize as 
discussed in Chapter 3. Randomization increases internal validity, thus lack of 
randomization results in poor internal validity. Without internal validity, the clinical 
trial is meaningless and unethical. 
 
Lack of scientific validity for some CMs clinical trials leads to compromised 
research and undermines the justification for doing the research. In addition to 
providing invalid information of the CMs in question, and exposing study 
participants to unnecessary harms, the lack of validity caused by inappropriate 
study design can have far reaching effects. As RCTs involve considerable 
resources, conducting trials with questionable validity waste time, manpower and 
financial resources that could have been more effectively spent elsewhere.  
Indeed, in a resource-constrained country such as S. A., any profligacy with 
national resources must be considered highly inappropriate.  
 
                                            
16 Other words for external validity are generalizabilty, applicability and 
transferability. 
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Moreover, poor understanding of CMs or unrepresentative information on CMs 
could lead to poor policy decisions by the government, compounding an already 
complex system of national health provision. 
 
5.2 CONSIDERING THE PROTECTION OF PARTICIPANTS IN CMs CLINICAL 
TRIALS IN S.A  
 
The protection of trial participants is a fundamental element of any study design. It 
is commonly agreed that “even though risks are inevitable in clinical trials, it is 
important that those risks are assessed and minimized and that any anticipated 
harms be monitored, reported and managed” (Califf et al. 2003: 257). While the 
researchers are obligated to ensure that the risks of participation are as low as 
possible, it is commonly assumed that participants are willing to take on these 
risks due to the range of benefits also associated with participation. 
 
According to Bake (2006: 13) benefits of participating in a clinical trial includes the 
following: “playing an active role in your own health, gaining access to the new 
research treatment way before they are available to the public, obtaining expert 
care as highly qualified and leading facilities are there during the trial and lastly 
being able to help others by contributing to the medical research.” 
 
Clinical trials oversight is a very important element in ensuring the protection of 
participants. According to Dhai & McQuoid-Mason (2011: 170) the safety of 
participants in clinical trials in S.A are protected by the Research Ethics 
Committees (RECs) of research institutes, Data and Safety Monitoring Boards 
(DSMBs) and MCC These committees which are charged with overseeing clinical 
trials uphold the three basic principles of Belmont Report which are Respect for 
Persons, Beneficence and Justice.  
 
According to the SAGCP(2006: 58), the RECs also “provides public assurance of 
the protection by reviewing, approving and providing comment on clinical trial 
protocols, the suitability of the investigator(s) and procedures used to obtain 
informed consent. The RECs are guided by the relevant South African ethical 
guidelines”. The main role of the RECs is to safeguard the dignity, rights, safety, 
 
  
   ~ 32 ~ 
and well-being of all trial participants in clinical trials (Califf et al., 2003: 257). They 
are also expected to judge protocols based on scientific merit and the expectation 
of valid results. RECs are expected to take full responsibility of the clinical trial 
they approve as well as protect the participants from the harm that may arise from 
poor research. 
 
As already discussed in section 4.4 of chapter 4, there are currently no guidelines 
specifically for CMs clinical trials in S.A and poor regulation of CMs clinical trials 
thus places RECs in a difficult position as they must pass judgment on unclear 
protocols. In the absence of guidelines for CMs clinical trials, the risks to the 
patients cannot be properly assessed as there will be no standards to adhere to. 
This has a huge impact on the mandate of the RECs as they will not be able to 
protect the welfare of the participants in the absence of guidelines. This places 
unnecessary strain on RECs, and can lead to serious complications including the 
undermining of the authority of the REC as well as personal challenges for 
individual members. 
 
 
The RECs have a legal obligation to the government for patient safety according to 
the National Health Act. In terms of law, the National Health Act has provisions for 
the protection of the participants and researchers who ignore or fail to adhere to 
those provisions may be guilty of a criminal offense. This Act is enforceable and 
has powers to prosecute. The protection of participants in health-related research 
is also supported by international documents such as World Medical Association’s 
1964 Declaration of Helsinki, Belmont Report and the Council of International 
Organizations of Medical Sciences International Ethical Guidelines. Thus, the 
perpetuation of potentially flawed CM RCT study designs can cause considerable 
problems for those appointed to positions of responsibility and authority.  
 
 
5.3 INFORMED CONSENT AND AUTONOMY 
 
Linked to issues of patient protection is the importance of informed consent in 
clinical trials, which reflects the obligation to respect persons and their 
autonomous decisions (Beauchamp & Childress, 2009: 119). It is expected that 
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when informed consent is adequately administered that a person is accurately 
informed of the purpose, methods, risks, benefits of the research and gives an un-
coerced decision to participate (Beauchamp & Childress, 2009: 120). 
 
Respect for autonomy and informed consent are inseparable (Hall et al., 2012: 
533). “The elements of adequate informed consent include full disclosure, 
comprehension of information, voluntariness and competence to consent” 
(Beauchamp & Childress, 2009: 120). This reflects a three stage process, where 
the participant is given full and accurate information about the purpose of the RCT, 
the possible risks, and the extent of their expected involvement. They then have 
the opportunity to reflect and question the information given, before making an 
autonomous decision about their possible involvement.  
 
Flawed guidelines for CMs clinical trials in S.A tend to overlook the difficulties of 
informed consent. For an example, CMs therapies have a spiritual component so it 
may be necessary to describe that in the guidelines. The SAGCP guidelines 
(2006: 11) only state that “obtaining informed consent implies the provision of 
information to potential participants regarding the nature of the research 
procedure, scientific purpose and alternatives to study participation” and it does 
not state anything about a spiritual component of CMs. Some researchers in CMs 
clinical trials do not disclose or inform participants about the spiritual component of 
CMs and this is problematic as it limits consent and it is not full disclosure.  
 
There are also instances whereby the researchers in CMs clinical trials undertake 
to give a CM to participant/s without knowing what the active constituent is or even 
other substances/ constituents, what the correct dosage is and also what risks are 
involved. In these instances, it is really impossible for participants to consent or 
this limits the process of informed consent as one cannot give consent to the 
unknown. The process of informed consent involves disclosing the risks and 
benefits of the trial. 
 
Current guidelines thus place both practitioner and patient in difficult positions.  
The patient’s ability to make informed autonomous decisions is impacted by the 
lack of information about CM actions and efficacy, which potentially exposes them 
to unforeseen risks. Conversely, the practitioners, by not being able to offer such 
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information, are not able to fulfil their duties to beneficence and non-maleficence 
as expected by their profession and peers. Both, thus, are compromised in their 
abilities to act as autonomous agents. 
 
5.4 RESEARCHER INTEGRITY 
 
Performing research or a clinical trial requires integrity. According to Piacentini 
(2013: 21) “to have integrity in a research is to aim for wholeness, positivity and to 
produce workable frameworks that enhance performance in the research field”. 
Without integrity, there is no accountability and the ethical, careful and honest 
measures we put into place to ensure we protect our participant’s confidentiality 
will fall apart. In a clinical trial, a researcher must adhere to moral principles. 
According to Dhai & McQuoid-Mason (2011: 32) “researchers should incorporate 
these core ethical values and standards as the foundation for their character and 
practice as responsible researchers”. 
 
Lack of guidelines for CMs clinical trials as it is the situation right now in S.A may 
put researchers into difficult situations or ethically compromising moments as they 
cannot commit to fully safeguarding participants in instances of harm or may not 
know what to do. Secondly, in the absence of guidelines for CMs clinical trials, 
there will be no standards to adhere to and this can facilitate researchers towards 
non-compliance and this may have a huge significance for patient safety. The 
flawed system may also put an unaware researcher in a compromised position of 
not performing the clinical trial to the highest standard of professionalism and in an 
ethically robust manner. Flawed systems can also test the unaware or not 
adequately trained researcher’s ability to maintain ethical standards.  
 
Heimer (2013: 373) in her article mentioned that “if people do not have any place 
to sit while they do their work, they are likely to fill out the forms correctly or check 
them. If there is not a clock, they can’t document the time if they don’t themselves 
own watches. If there is not locking cabinet, they can’t store their work securely”.  
This can be applied to the current situation of lack of guidelines for CMs clinical 
trials. If there are no guidelines, researchers cannot be expected to try and be 
ethical. Researchers may also not follow any protocol when running the clinical 
trials of CMs as there are no systems in place.  In the absence of guidelines the 
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researchers cannot guarantee or secure safety for participants as mentioned 
previously. In conclusion In conclusion, the government should not have any 
expectations that those researchers in CMs clinical trials to be ethical unless they 
have systems in place such as the much needed guidelines for CMs clinical trials. 
 
5.5 GOVERNMENTAL RESPONSIBILITY 
 
The government has obligations to improve health provision. These 
responsibilities are in line with the three key ethical principles identified in 
bioethics: beneficence, non-maleficence and justice. The government has key 
responsibilities to the public to uphold all three – something that is undermined by 
the current status of CM RCTs in S.A. 
 
The principle of beneficence in bioethics involves the obligation to promote good, 
act in the best interest of others and the society to prevent, remove, minimize 
harm and risk and also promoting and enhancing the good of a person (Dhai & 
McQuoid-Mason, 2011: 14). This principle gives rise to norms requiring that the 
risks of research practice to be reasonable in the light of the expected benefits, 
that the research design is sound, and that the investigators or researchers be 
competent both to conduct the research and to safeguard the welfare of the 
research subjects. 
 
In order to maximize the benefit to the participants of CMs clinical trials, the S.A 
government should ensure that guidelines on CMs clinical trials are drawn and put 
into place. By not having guidelines for CMs clinical trials, society is not benefitting 
at all. This also puts the promise of healthcare to the population in jeopardy. It also 
wastes resources and time. Clinical trials as discussed previously are beneficial as 
new drugs could be discovered which will reduce the burden of high disease rate.  
 
Principle of beneficence is closely related to the principle of non-maleficence. 
According to Beauchamp&Childress (2009: 149) “The principle of non-maleficence 
imposes an obligation not to inflict harm on others”. The government has a strong 
obligation towards non-maleficence as exemplified in the Batho Pele principles. By 
allowing RCTs to continue when the REC oversight and researcher integrity can 
be potentially compromised by the inappropriate guidelines, the government 
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violates the principle of non-maleficence. Indeed, they voluntarily perpetuate 
situations in which participants are potentially placed at risk.  
 
The principle of justice is defined by Beauchamp & Childress (2009: 241) as the 
“fair, equitable, and appropriate treatment in light of what is due or owed to 
persons”. This principle recognizes that people should be treated fairly and in 
accordance with what is morally right. “The principle of justice is an important 
factor in resource allocation decisions” (Dhai & McQuoid-Mason, 2011: 145). The 
promotion of flawed guidelines for CMs clinical trials could result in a waste of 
resources, wastes time, and this as stated in the last paragraph puts the promise 
of healthcare for the population in jeopardy. In resource-limited healthcare system 
like the one in S.A, guidelines are needed to improve the efficiency of health care , 
cost effectiveness and to  free up resources needed for other healthcare services.  
 
The government is perpetuating non-effective medicines to be part of the health 
provision in the absence of guidelines. It can also be said that due to lack of 
guidelines for CMs clinical trials, the society is also being robbed of medicines 
which might be effective in the treatment of diseases. 
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CHAPTER 6: SUMMARY AND CONCLUDING REMARKS 
 
 
Despite the issues identified in chapter 5, S.A. still needs some form of oversight 
for the clinical trials of CMs – particularly as S.A moves towards a more universal 
and government-mediated healthcare system such as the NHI which will ensure 
that all South Africans have access to quality health care services. Thus, we have 
to ask, what systems could assist in better regulating CMs? This chapter 
concludes the report and makes recommendations for clinical trials of CMs in S.A. 
 
6.1 RECOMMENDATIONS FOR CMs CLINICAL TRIALS IN S.A 
 
This section will provide recommendations on how to conduct CMs clinical trials in 
S.A. As stated in the previous chapters, there are currently no specific guidelines 
or framework in place for clinical trials of CMs in S.A. The absence of guidelines 
for clinical trials of CMs in S.A affects the approval process of clinical trials of CMs.  
 
6.1.1 POLICY MAKERS 
 
There is an urgent need of comprehensive review of current policy and the 
development of specific policies for CM clinical trials. The MCC should establish a 
clinical trial Sub-Committee for CMs/Plant Based Medicines which will be 
responsible for developing guidelines that are appropriate, relevant and 
specifically for clinical trials of CMs or Plant-Based Medicines. The Sub-Committee 
should be given a specific time limit to complete the development of those 
guidelines as there is an urgent need of these guidelines.  
 
The Sub-Committee should compromise of members with interest in clinical trials 
of CMs. The different stakeholders should also be involved in the development of 
guidelines for CMs such as researchers, Allopathic Medical Doctors, CMs 
practitioners, the pharmaceutical industry and healthcare policy makers. It is 
possible that the CSIR (Council for Scientific and Industrial Research), MRC and 
the NDOH could work together to collate all existing knowledge of CMs into an 
easily accessible database.  
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6.1.2 FOR FUTURE CMs RESEARCH 
 
The MCC should initiate properly designed and conducts RCTs of all CMs. Even 
though some of the CMs cannot meet the criteria established for Allopathic 
Medicines as already discussed in Chapter 3, the MCC must work with clinical 
research organizations to address these issues in order to evaluate CMs products. 
The clinical trials sub-committee for CMs/Plant Based Medicines should be guided 
by the international regulatory agencies such as WHO and Australian guidelines 
for the development of the guidelines. 
 
The guidelines should also state that traditional use of CMs should not be a 
substitute for safety but must be taken into consideration when safety is evaluated. 
When traditional use is used as safety evidence, the details of use (such as 
duration, route, dose, etc) should be consistent with the proposed use. Where data 
of traditional use is insufficient, the safety evaluation will need to be supported with 
other studies such as animal studies and more basic science studies. 
 
The guidelines should also accommodate CMs products that are already on the 
market. For those products because of their long-term use, phase 2 and phase 3 
studies may be conducted while those products are on the market. The dosage 
form was not mentioned in SAGCP guidelines. The dose of any CMs will only be 
determined by the dose used by the CMs practitioner. 
 
It is also necessary to develop a new method for the evaluation of CMs to use in 
place of the current RCT approach. There is evidence of alternatives (such as 
case control studies, cross-sectional studies, cohort studies and case reports 
studies discussed in section 3.5.5, pages 17-18). These may provide some 
solutions to the ethical and practical problems listed above, but require 
considerable further investigation.  
 
While authors such as Verhoef (2005) recognize the benefits of these alternative 
methods, more empirical evidence needs to be gathered before they can be 
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reliably recommended as alternatives to RCTs. Indeed, it is possible that a new 
“middle ground” between RCTs and these alternative methods also need to be 
explored. We need more understanding of where the current approach is failing 
and new evidence on alternatives. 
 
RCTs for CMs show clear evidence of potential participant harm. Therefore, new 
strategies that address:  a) the inability to adequately consent participants, b) 
control for unexpected outcomes in a more regulated manner and c) allow for 
scientifically valid and valuable comparisons between treatment regimes. 
 
As described above, in order to advance the current framework we first need to 
know where the current framework failed in order to give it a new direction. The 
current guidelines do not suits CMs clinical trials as described in Chapter 3. Some 
areas of the guidelines need to be changed to accommodate the individual needs 
of CMs. I would suggest that other regulatory agencies guidelines such as WHO 
and FDA be critically examined for ways in which they could contribute towards 
developing the SAGCP. Alternatively, new guidelines for CMs clinical trials need to 
be drafted. 
 
 
6.2 CONCLUDING REMARKS 
 
Investigations into the safety of CMs are important and necessary to safeguard the 
interests of the public. The various methods can be used to determine the safety 
and efficacy of CMs but it is very important to know of these options in order to 
always carry out the best possible research. Safety must never be assumed but it 
must be demonstrated using adequate research methods. The challenges 
currently faced in CMs clinical trials in S.A can only be overcome by having a set 
of guidelines specifically for CMs clinical trials. The government need to ensure 
that there are guidelines for CMs clinical trials in order to uphold the principles of 
non maleficence, beneficence and justice. 
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